A Warning, a Trial, and a Ledger

Opening Sermon · Fiction

FICTIONAL CONTINUITY: Epistide placed a warning label beside a promising trial. “Both belong on the front page,” he told Doctide. The headline complained about the lack of elbow room.

Regulatory Gospel · Approved use and safety

November 9 regulatory action: FDA requires GLP-1 receptor agonist labels to warn about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden, painless vision loss that can be permanent. This is a safety-label change, not a withdrawal or a new indication. FDA safety communication, November 9, 2026.

Controlled safety evidence: FDA’s analysis of 126 randomized trials found 15 probable events: rates were 6.4 versus 3.8 per 100,000 person-years for GLP-1 medicines versus comparators. Rare events and pooled products limit individual-drug conclusions.

Human Record · Observational evidence

FDA’s Sentinel analysis found no statistically significant difference against SGLT-2 inhibitors (HR 1.19; 95% CI 0.91–1.54), but an increase against DPP-4 inhibitors (HR 1.43; 1.02–2.01). Comparator choice matters. Spontaneous reports were difficult to interpret because underlying conditions share risk factors. These findings must not be collapsed into a claim that every reported case was caused by treatment. FDA analysis, November 9.

Scientific Revelations · Controlled human evidence

Peer-reviewed retatrutide evidence: A November 8 NEJM paper reports two randomized phase 3 trials in adults with painful knee osteoarthritis and overweight/obesity, without diabetes. TRIUMPH-4 enrolled 445 people; TRIUMPH-1-OA enrolled 574. At 68 weeks in TRIUMPH-4, active groups improved pain by 3.74–3.96 points versus 2.12 with placebo on the 0–10 WOMAC scale, using the hybrid-treatment estimand. Weight declined 20.0–23.7% versus 4.6%.

Intention-to-treat analyses also favored retatrutide. Gastrointestinal events were most common; serious adverse events were more frequent in active groups. Retatrutide remains investigational. This is evidence for the studied population and outcomes, not proof of cartilage regeneration or a new approval. Lilly funded the trials. Schnitzer and colleagues, NEJM, November 8.

Updated combination-trial disclosure: Lilly’s November 11 TOGETHER-PsA report describes 271 randomized participants in an assessor-blinded, open-label trial. At week 52, ACR50 responses were 43.7% with ixekizumab plus tirzepatide versus 15.7% with ixekizumab alone. These are prespecified exploratory analyses without multiplicity control; they are distinct from the week-36 primary endpoint. Gastrointestinal symptoms were among common combination-arm adverse events. Lilly reports simultaneous journal publication; this summary uses its release, not a complete independent appraisal of the paper. No new combination indication is established here. Lilly, November 11.

Adjacent non-peptide research: Lilly reported positive phase 3 ATTAIN-OSA results for orforglipron on November 9, with presentation at AHA and publication in JAMA. Its planned OSA submission by year-end remains a future regulatory step. Orforglipron is a small molecule, not a peptide; an existing weight-management approval does not authorize every studied use. Detailed numerical comparisons are deferred pending appraisal of the full trial report. Lilly, November 9.

From the Laboratory · Evidence boundaries

Animal research: FDA’s animal-data review did not identify a mechanism explaining the potential NAION risk. FDA, November 9.

In-vitro mechanisms: No material new cell-based finding met this edition’s verification threshold.

Unsupported inference: A plausible mechanism cannot establish human benefit; improved symptoms do not by themselves establish tissue repair. Commercial availability is also not evidence of effectiveness.

Market Tithe · Profitide, fictional Keeper of the Market Tithe

FICTIONAL COMMENT—PROFITIDE: “The revenue grew. The margin would like a word.”

Confirmed company disclosure: Hims & Hers (HIMS) reported November 9 quarterly revenue of $890.4 million, up 49%, with gross margin of 57% versus 74% a year earlier. It reported a $33.0 million net loss alongside $82.4 million adjusted EBITDA. The latter is a non-GAAP measure, not net profit. Full-year adjusted EBITDA guidance was reduced to $257–277 million. Company financial release, November 9.

Confirmed commercial agreement: Lilly and Hims announced an agreement concerning access to approved Lilly medicines on November 6. This is a distribution/platform development, not new clinical evidence, a new medicine approval or a verified licensing milestone. Joint announcement, November 6.

Manufacturing plans—reported, not completed: Reuters reported Hims’ plans for a November wellness-product launch and later U.S. production of BPC-157 and TB-500. Plans do not establish completed manufacture, validated quality or FDA approval. NAD+, also mentioned in the rollout, is a coenzyme, not a peptide. Reuters, November 9 report.

Dated market movement: No sufficiently verified price-and-time observation is included this week; no stock move is attributed to a single headline.

Editorial inference: Revenue growth and wider distribution can coexist with margin pressure and unresolved clinical questions. No additional material licensing transaction met this review’s verification threshold.

Movements in the Canon / Those Awaiting Canonization

No canon or character change. A trial result and a commercial rollout do not confer regulatory approval.

Further Reading · Deeper lecture

Reading benefit, risk and business on separate pages

1. Absolute event rates versus relative risks.
2. Why observational comparators change the result.
3. Hybrid versus intention-to-treat trial estimates.
4. Exploratory endpoints and multiplicity.
5. Revenue, margin, GAAP loss and adjusted EBITDA.

Sacred Footnotes · Interests and limitations

Last reviewed November 12, 2026. Evidence window: November 5–11; edition date: November 13; first published November 12. Lilly funded the retatrutide research and has commercial interests in its trial and partnership announcements; Lilly employees are among the NEJM authors. Hims has commercial interests in its financial and rollout disclosures.

The NEJM abstract and funding notes, FDA communication and cited company releases were reviewed. Complete trial supplements, individual disclosure forms and the additional journal reports were not fully appraised. Manufacturing plans were reported through Reuters and not independently inspected. No independent clinical review is claimed.

Educational reporting only. No treatment, dosing, sourcing, medical or investment advice.